The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
The issuer is solely responsible for the content of this announcement.
Improving GLP-1 drug delivery by 'painting' it on antibodies
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Future Market Insights18d
Global Epinephrine Auto-Injector Market Poised for Significant Growth USD 3,394.4 million by 2034 Amid Rising Allergy Cases | FMI
The global epinephrine auto-injector market is set for steady expansion, driven by the increasing prevalence of severe allergies worldwide. According to market projections, global sales of epinephrine ...
GitHub19d
OpenTelemetry Operator for Kubernetes
You can install Opentelemetry Operator via Helm Chart from the opentelemetry-helm-charts repository. More information is available in here. WARNING: Until the ...
BMJ27d
Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study
Canada Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with ...
Reuters28d
Lilly offers weight-loss drugs in vials at a discount to fight competition
New pricing aims to attract cash-paying customers via LillyDirect Hims & Hers warns it may stop selling compounded version of Novo Nordisk weight-loss drugs Telehealth firms' shares fall The move ...
autoevolution29d
Android Auto 13.8 Now Available for All Users With a Major Fix
Google has just started the rollout of a new Android Auto update, and the good news is that this version seems to resolve a major glitch hitting wireless users. Before delving into details ...